A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

开始日期2024-12-30

申办/合作机构

Brown University

[+2]

NCT06725121

/ Recruiting临床1/2期IIT

Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial

The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation.
The main questions it aims to answer are:
* How many patients will achieve transplant with this treatment strategy?
* What will the 5-year survival and recurrence-free survival rates be for these patients?
Participants will:
* Undergo a biopsy of the tumor.
* Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months.
* Be referred for a liver transplant and undergo the procedure if deemed eligible and safe.
* If applicable, be followed for five years post-transplant with regular data collection.

开始日期2024-12-01

申办/合作机构

University Health Network

NCT05692037

/ Recruiting临床1/2期IIT

Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases: A Multicentre, Prospective, Open-label, Single-arm Trial

To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases

开始日期2022-12-28

申办/合作机构

东南大学附属中大医院

100 项与钇90 相关的临床结果

登录后查看更多信息

100 项与钇90 相关的转化医学

登录后查看更多信息

100 项与钇90 相关的专利（医药）

登录后查看更多信息

1,101

项与钇90 相关的文献（医药）

2025-03-01·APPLIED RADIATION AND ISOTOPES

Multi-dose formulation and clinical deployment of [90Y]Y-labeled hydroxyapatite (HA) microparticles for radiation synovectomy in India– the inherent intricacies

Article

作者: Rajeswari, A ; Patra, Sourav ; Chakraborty, Sudipta ; Kamaleshwaran, K K ; Vimalnath, K V

The present article describes intricate details involved in the formulation and quality control of 113 ready to use doses of [⁹⁰Y]Y-labeled hydroxyapatite (HA) microparticles for clinical use in radiation synovectomy using ⁹⁰Y produced by (n,γ) route. Yttrium-90 was produced with a specific activity of 720 ± 95 MBq/mg of Y and radionuclidic purity of >99.9%. Optimized protocol developed for one-step formulation of [⁹⁰Y]Y-HA microparticles was adopted to prepare the clinical doses (400 ± 50 MBq ⁹⁰Y in each dose) in 20 batches. The radiochemical purity of the product was >99.0% in all 20 batches and all other quality control parameters were as per the monogram approved for its clinical use in India. More than 100 patients suffering from inflammatory joint diseases of mainly knee joints were treated with doses of [⁹⁰Y]Y-HA microparticles. Clinical investigations post-treatment demonstrated the effectiveness of the formulation in the management of the disease.

2024-12-01·American journal of ophthalmology case reports

Yttrium-90 (90Y) brachytherapy for squamous carcinoma: Treatment of the conjunctiva, cornea, and sclera

Article

作者: Finger, Paul T ; Maniar, Arpita ; Materin, Miguel A. ; Chino, Junzo ; Meltsner, Sheridan ; Materin, Miguel A ; Finger, Paul T.

Purpose:

Patients with conjunctival squamous cell carcinoma that present with persisting disease or recurrence following topical chemotherapy and/or surgery especially when invading the sclera are challenging to treat. Herein, we describe the use of high-dose-rate (HDR), FDA-cleared, yttrium-90 (⁹⁰Y) plaque brachytherapy for such lesions.

Observation:

Three cases of invasive conjunctival squamous cell carcinoma that had exhibited a poor response or recurrence following topical chemotherapy and/or surgery are described. As treatment, HDR ⁹⁰Y beta-radiation was applied to the tumor and margins for a single, continuous duration. In contrast to low-dose-rate (LDR) plaque, HDR ⁹⁰Y brachytherapy did not require episcleral sutures, amniotic membrane buffering of the cornea, a Gunderson flap, outpatient dwell time, or second surgery. Radiation safety was improved by eliminating LDR-implant related post-operative radiation exposure to health care personnel, the community, family, and pets. Follow-up examination at one month revealed complete tumor resolution in all patients. At last follow-up (8, 11 and 18 months) all patients remained clinically tumor-free as confirmed by slit-lamp biomicroscopy, anterior segment optical coherence tomography, and high-frequency ultrasound imaging. There were no acute complications (e.g., corneal edema, iridocyclitis, scleropathy, keratopathy or cataract).

Conclusion and Importance:

⁹⁰Y brachytherapy demonstrated efficacy as a single-surgery, minimally invasive, outpatient irradiation for squamous carcinoma of the ocular surface. While short-term results were promising, long-term follow-up monitoring for side-effects and recurrence are essential.

2024-12-01·JOURNAL OF GASTROINTESTINAL SURGERY

Use of selective internal radiation therapy with yttrium-90 as a bridge to liver resection: a 5-year single-center experience

Article

作者: Kalra, Aryan ; Rowcroft, Alistair ; Ballal, Mohammed ; Bhandari, Mayank ; Trinder, Matthew

BACKGROUND:

Selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) has been historically reserved for unresectable liver malignancy. Evidence is emerging for the use of SIRT to increase future liver remnant (FLR), allowing for the resection of previously inoperable disease.

METHODS:

This was a 5-year retrospective review of all patients undergoing SIRT with Y-90 at a tertiary institute. Patient demographics, clinicopathologic data, surgical details, and postoperative outcomes were reviewed. The primary outcome, safety of liver resection after SIRT, was evaluated with 90-day morbidity and mortality.

RESULTS:

A total of 134 SIRT procedures were performed on 113 patients. Post-SIRT complications occurred in 18 patients (15.9%), with a single 30-day mortality. In addition, 17 patients underwent SIRT with the intent to augment FLR for liver resection. After SIRT, mean hepatic mebrofenin extraction and FLR increased from 2.5%/min/m² and 30.5% to 4.2%/min/m² and 52.5% (P = .01 and P < .0001, respectively). Ten patients underwent resection, and there were 2 intraoperative complications. The median time from SIRT to resection was 5.2 months. The 90-day postoperative morbidity was 20% (n = 2), and complications were analyzed according to the Clavien-Dindo II classification scale. There was no 30-day or 90-day postoperative mortality.

CONCLUSION:

Post-SIRT liver resection is a challenging procedure with low postoperative mortality and morbidity.

项与钇90 相关的新闻（医药）

2024-11-22

·PipelineReview

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany I November 21, 2024 I Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by the French Ministry of Health and led by a renowned investigator team from the University Hospital in Nantes, represents a significant step toward expanding targeted radiotherapy options for hematologic malignancies. The investor-initiated study, named PENTILULA (ClinicalTrials.gov ID: NCT06356922) is a multicenter, open-label trial in which up to 21 patients with relapsed/refractory AML or ALL will be enrolled over a period of 24 months, with a total study duration of 36 months. The primary objective is to determine the maximal tolerated dose (MTD) of Lu177-PentixaTher, and to examine key efficacy parameters such as overall response rate (ORR) and complete remission (CR) after infusion of the novel radiotherapeutic agent. Following a peer-reviewed publication in January 2023 in the prestigious Journal of Nuclear Medicine highlighting promising clinical results in the treatment of patients suffering from T-cell lymphoma, further evidence continues to be built up about the potential of Pentixapharm’s lead candidate, PentixaTher, for the treatment of haemato-oncological diseases. The study is significant for Pentixapharm insofar as the incidence of ALL and AML, and hence the medical need, is much higher than that for T-Cell lymphoma. The PENTILULA trial is the first trial that combines PentixaTher with Lutetium-177, a radioisotope widely and successfully used for the treatment of castration resistant prostate cancer or neuroendocrine tumors. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive and life-threatening blood cancers that affect thousands of people worldwide each year. AML is the most common type of acute leukemia in adults, with an incidence of approximately 20,000 new cases per year and low five-year survival rate of 31.9% in the United States [1]. ALL is the most common type of cancer in children, with a high incidence in adults as well. Current treatment options often involve intensive chemotherapy and stem cell transplantation, which can have severe side effects. Effective radiotherapies in other indications are currently reimbursed with more than 100,000 USD per patient. “Although treatments for acute leukemia have advanced, many patients continue to have limited options and face poor outcomes. We believe PentixaTher holds significant potential to address these unmet needs, offering a valuable radiopharmaceutical theranostic approach tailored to the individual patients with hematologic malignancies,” explains Dr. Dirk Pleimes, Group CEO and CMO at Pentixapharm. “We are delighted that leading experts such as Professor Françoise Kraeber-Bodéré of the Nuclear Medicine Department and Professor Patrice Chevallier of the Hematology Department in Nantes have decided to initiate this study to evaluate this novel radiotherapeutic treatment option. We are committed to providing our full support, leveraging our therapeutic knowledge with PentixaTher and facilitating access to the compound to drive this important research forward.” Professor Françoise Kraeber-Bodéré is the Head of the department of Nuclear Medicine at the University Hospital in Nantes, France, and an expert of the Oncology committee of the French Society of Nuclear Medicine (SFMN) as well as of the Oncology and Therapy committee of the European Association of Nuclear Medicine. She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist in Hematology and member of the executive committee and scientific council of HéMA, an umbrella organization for hemato-oncological research in Western France. About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Its Pipeline includes PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68 based companion diagnostic for blood cancers and cardiovascular diseases. PentixaTher is an innovative radiotherapeutic that specifically targets the chemokine-4 receptor (CXCR4). Background material about its potential for the treatment of haematooncological diseases can be found at: About Nantes University Hospital Nantes University Hospital (CHU de Nantes) is one of France’s leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting thousands of clinical trials and contributing to significant advancements in healthcare. [1] https://seer.cancer.gov/statfacts/html/amyl.html SOURCE: Pentixapharm

临床研究

2024-11-21

·GlobeNewswire-Health Care

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by the French Ministry of Health and led by a renowned investigator team from the University Hospital in Nantes, represents a significant step toward expanding targeted radiotherapy options for hematologic malignancies. The investor-initiated study, named PENTILULA (ClinicalTrials.gov ID: NCT06356922) is a multicenter, open-label trial in which up to 21 patients with relapsed/refractory AML or ALL will be enrolled over a period of 24 months, with a total study duration of 36 months. The primary objective is to determine the maximal tolerated dose (MTD) of Lu177-PentixaTher, and to examine key efficacy parameters such as overall response rate (ORR) and complete remission (CR) after infusion of the novel radiotherapeutic agent. Following a peer-reviewed publication in January 2023 in the prestigious Journal of Nuclear Medicine highlighting promising clinical results in the treatment of patients suffering from T-cell lymphoma, further evidence continues to be built up about the potential of Pentixapharm’s lead candidate, PentixaTher, for the treatment of haemato-oncological diseases. The study is significant for Pentixapharm insofar as the incidence of ALL and AML, and hence the medical need, is much higher than that for T-Cell lymphoma. The PENTILULA trial is the first trial that combines PentixaTher with Lutetium-177, a radioisotope widely and successfully used for the treatment of castration resistant prostate cancer or neuroendocrine tumors. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive and life-threatening blood cancers that affect thousands of people worldwide each year. AML is the most common type of acute leukemia in adults, with an incidence of approximately 20,000 new cases per year and low five-year survival rate of 31.9% in the United States [1]. ALL is the most common type of cancer in children, with a high incidence in adults as well. Current treatment options often involve intensive chemotherapy and stem cell transplantation, which can have severe side effects. Effective radiotherapies in other indications are currently reimbursed with more than 100,000 USD per patient. “Although treatments for acute leukemia have advanced, many patients continue to have limited options and face poor outcomes. We believe PentixaTher holds significant potential to address these unmet needs, offering a valuable radiopharmaceutical theranostic approach tailored to the individual patients with hematologic malignancies,” explains Dr. Dirk Pleimes, Group CEO and CMO at Pentixapharm. “We are delighted that leading experts such as Professor Françoise Kraeber-Bodéré of the Nuclear Medicine Department and Professor Patrice Chevallier of the Hematology Department in Nantes have decided to initiate this study to evaluate this novel radiotherapeutic treatment option. We are committed to providing our full support, leveraging our therapeutic knowledge with PentixaTher and facilitating access to the compound to drive this important research forward.” Professor Françoise Kraeber-Bodéré is the Head of the department of Nuclear Medicine at the University Hospital in Nantes, France, and an expert of the Oncology committee of the French Society of Nuclear Medicine (SFMN) as well as of the Oncology and Therapy committee of the European Association of Nuclear Medicine. She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist in Hematology and member of the executive committee and scientific council of HéMA, an umbrella organization for hemato-oncological research in Western France. About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Its Pipeline includes PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68 based companion diagnostic for blood cancers and cardiovascular diseases. PentixaTher is an innovative radiotherapeutic that specifically targets the chemokine-4 receptor (CXCR4). Background material about its potential for the treatment of haematooncological diseases can be found at: https://edoc.mdc-berlin.de/id/eprint/24012/1/24012oa.pdf About Nantes University Hospital Nantes University Hospital (CHU de Nantes) is one of France's leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting thousands of clinical trials and contributing to significant advancements in healthcare. For more information, please contact: Pentixapharm Holding AGPhillip Eckert, Investor Relationsir@pentixapharm.comTel. +49 30 94893232www.pentixapharm.com [1] https://seer.cancer.gov/statfacts/html/amyl.html

临床研究

2024-09-16

·PRNewswire

Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System

Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass., Sept. 16, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, today announced that it has received certification according to Medical Device Regulation (EU) 2017/745 for SIR-Spheres® Y-90 resin microspheres and its delivery systems, paving the way for the European launch of the SIROS™ Delivery System. The EU MDR places greater emphasis on patient safety measures, risk management, post-market surveillance, and comprehensive data collection for medical devices seeking European market access. "Patient health and safety are always at the forefront of our work. That is why we are particularly proud to receive EU MDR certification for SIR-Spheres® Y-90 resin microspheres and its delivery systems, including SIROS™. This achievement underscores our commitment to delivering innovative products responsibly and ethically," said Matt Schmidt, CEO of Sirtex Medical Inc. "With the expansion of SIROS™ outside of the U.S., interventional radiologists in Europe now have an additional option to support patients battling metastatic colorectal cancer (mCRC) and unresectable hepatocellular carcinoma (HCC). This milestone reflects the outstanding efforts of our team, the rapid growth of our business, and the groundbreaking interventional oncology solutions we have developed." The SIROS™ Delivery System offers an intuitive, visual, and adaptable solution for physicians to administer SIR-Spheres® to liver cancer patients. Its easy-to-use design along with controlled administration provides physicians confidence in the Y-90 delivery. "As an interventional radiologist, I am excited about the future use of the SIROS™ Delivery System," shared Professor Thomas Helmberger, Head of Department of Radiology, Neuroradiology, and Minimal-Invasive Therapy at München Klinik Bogenhausen in Munich, Germany. "This device has an intuitive design and a precise control that will facilitate the administration of SIR-Spheres® Y-90 resin microspheres, and I am looking forward to incorporating it into my practice." About SIR-Spheres® in Europe SIR-Spheres® are medical devices used in selective internal radiation therapy (SIRT) and are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy. For a complete listing of indications, contraindications, side effects, warnings, and precautions, please consult the Instructions for Use at . About Sirtex Sirtex is a global healthcare company with offices in the U.S., Australia, Europe, and Asia, dedicated to improving patients' quality of life and longevity through innovative, minimally invasive cancer and embolization therapies. Sirtex's current leading product, SIR-Spheres® Y-90 resin microspheres, offers targeted radiation therapy for liver cancer. For more information, visit . SOURCE Sirtex Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

放射疗法

100 项与钇90 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
诊断试剂	欧盟	CIS Bio International SA	2003-03-24
诊断试剂	冰岛	CIS Bio International SA	2003-03-24
诊断试剂	列支敦士登	CIS Bio International SA	2003-03-24
诊断试剂	挪威	CIS Bio International SA	2003-03-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床3期	中国	昆翎（天津）医药发展有限公司	2021-09-13
肝细胞癌	临床3期	中国	Biocompatibles UK Ltd.	2021-09-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_ASIA2024	N/A	不可切除的肝细胞癌	63	Yttrium-90 (Y-90) resin microspheres (SIRT with Y-90 resin microspheres)	鹹廠觸顧積夢遞夢壓淵(糧獵衊築膚選壓衊遞簾) = developed in 8 (12.7%) patients and no serious AE was reported 範遞壓鹽簾選繭製網醖 (齋遞艱願齋鏇糧製糧顧 ) 更多	积极	2024-12-07
ESMO_ASIA2024	N/A	不可切除的肝细胞癌	63	Yttrium-90 (Y-90) resin microspheres (SIRT with Y-90 resin microspheres)	願壓鏇膚願醖膚齋齋鹽(淵鏇艱築壓廠鏇觸襯製) = developed in 8 (12.7%) patients and no serious AE was reported 鹽醖憲願遞願齋餘鏇壓 (齋廠廠憲鑰窪鹹壓鹽壓 ) 更多	积极	2024-12-07
EASL_LCS2024	N/A	肝细胞癌	150	resin 90Y	選鏇鹹夢糧鬱鏇醖鏇艱(憲繭顧艱壓醖鹹衊膚艱) = 顧夢壓襯夢願積窪淵壓築選窪齋膚窪淵簾網鑰 (遞齋範膚膚遞顧觸壓積 ) 更多	积极	2024-02-22
EASL_LCS2024	N/A	肝细胞癌	150	resin 90Y	選鏇鹹夢糧鬱鏇醖鏇艱(憲繭顧艱壓醖鹹衊膚艱) = 願構顧遞鏇鏇觸鏇築醖築選窪齋膚窪淵簾網鑰 (遞齋範膚膚遞顧觸壓積 ) 更多	积极	2024-02-22
ASTRO2022	N/A	黑色素瘤	-	Yttrium-90 (90Y) (iWand AÂ® applicator)	獵築觸鏇餘顧顧觸築鹹(鹹積積廠獵構衊蓋窪鑰) = 鹹窪鹹積願遞醖憲衊齋鏇選遞憲鏇鏇糧積獵鬱 (繭餘積餘製艱遞繭醖獵 ) 更多	-	2022-11-01
EANM2022	N/A	肝细胞癌 90 Y glass microspheres	20	Yttrium-90 (Anatomic workflow)	願窪衊蓋遞齋構製鹹齋(鑰網鹹艱鹽範襯鑰獵鏇) = 鹽淵鏇窪網齋簾願齋餘蓋餘遞襯糧觸網鹽網廠 (選製憲夢糧簾構蓋構選 ) 更多	-	2022-09-22
EANM2022	N/A	肝细胞癌 90 Y glass microspheres	20	Yttrium-9099m Tc-MAA (99m Tc-MAA SPECT workflow)	願窪衊蓋遞齋構製鹹齋(鑰網鹹艱鹽範襯鑰獵鏇) = 憲鹽範夢繭網夢夢鹽範蓋餘遞襯糧觸網鹽網廠 (選製憲夢糧簾構蓋構選 ) 更多	-	2022-09-22
SNMMI2022	N/A	-	-	Y-90 (Y90 SIR-Spheres)	鏇憲蓋選衊鏇觸壓廠憲(鹹鹹憲夢膚鹹壓餘鑰積) = 鏇簾顧願艱鹹淵築窪築築鹹餘壓鹽獵糧膚選壓 (齋膚鹽衊選艱築觸獵憲 )	-	2022-08-08
SNMMI2022	N/A	-	-	Y-90 (TheraSphere)	鏇憲蓋選衊鏇觸壓廠憲(鹹鹹憲夢膚鹹壓餘鑰積) = 淵築艱壓齋餘顧醖顧淵築鹹餘壓鹽獵糧膚選壓 (齋膚鹽衊選艱築觸獵憲 )	-	2022-08-08
SNMMI2022	N/A	肝细胞癌	-	Yttrium-90 (90Y-glass radioembolization)	膚範憲築鏇鑰膚齋繭齋(鏇選積觸願積繭壓鑰繭) = 遞窪築餘選積選繭遞範選鑰範壓糧獵顧餘構製 (範鏇糧鹽製齋鬱襯糧獵 )	-	2022-08-08
SNMMI2021	N/A	肝转移	35	yttrium 90 (Patients with metastatic liver disease)	憲觸積夢衊餘憲獵衊醖(齋齋獵鏇選獵淵獵觸衊) = 衊積鏇憲淵構簾構淵糧憲積艱鹽鹹襯鬱膚選願 (鹽餘廠糧鬱鑰築夢鏇構, 4.9 (IQR 3.9 ~ 7.1)) 更多	积极	2021-05-18
EANM2020	N/A	-	-	Yttrium-90 (SiPM-based PET/CT)	壓鏇壓範蓋顧鏇簾廠蓋(構鏇網網鬱襯廠願壓醖) = 憲觸觸襯鏇淵膚糧衊觸願壓顧範構觸構壓網憲 (糧壓顧醖夢鹹醖糧餘網 ) 更多	-	2020-09-18
EANM2020	N/A	-	-	yttrium-90 (Plastic syringe shield)	積範蓋壓夢餘獵餘簾憲(蓋構鑰顧積襯膚遞淵範) = 鑰艱齋製齋窪獵鏇醖鹽築鹹積網觸淵艱夢繭願 (膚鹹鑰壓蓋膚壓醖淵窪 ) 更多	-	2020-09-18
EANM2020	N/A	-	-	yttrium-90 (High energy tungsten syringe shield)	積範蓋壓夢餘獵餘簾憲(蓋構鑰顧積襯膚遞淵範) = 廠遞淵襯製鹹繭齋鑰遞築鹹積網觸淵艱夢繭願 (膚鹹鑰壓蓋膚壓醖淵窪 ) 更多	-	2020-09-18